Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of NCAM1 autoantibody detection reagent to preparation of lung cancer screening kit

A technology of autoantibodies and kits, applied in measuring devices, instruments, scientific instruments, etc., can solve the problems of no lung cancer, no NCAM1 protein, etc., and achieve good application prospects, effective screening, and low patient harm.

Active Publication Date: 2019-11-05
WEST CHINA HOSPITAL SICHUAN UNIV +1
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are no related reports on NCAM1 protein autoantibodies, and there is no prior art related to lung cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of NCAM1 autoantibody detection reagent to preparation of lung cancer screening kit
  • Application of NCAM1 autoantibody detection reagent to preparation of lung cancer screening kit
  • Application of NCAM1 autoantibody detection reagent to preparation of lung cancer screening kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1 Relationship between NCAM1 autoantibodies in plasma and lung cancer 1. Clinical data

[0027] Select 30 cases of lung cancer patients, 29 cases of benign lung diseases (tuberculosis, hamartoma and other non-malignant tumors), and 30 cases of healthy controls. The basic information is as follows:

[0028] Basic Information lung cancer patients benign lung disease healthy control number of people 30 29 30 age 58±10.5 46.5±10.0 42±8.9 male ratio 20(66.7) 12(41.4％) 13(46.7％)

[0029] 2. Detection principle

[0030] HuProt TM NCAM1 protein is immobilized on the human protein custom chip. After incubation with serum, NCAM1 autoantibodies (mainly including IgG, IgM antibodies, and some other types of antibodies) in the serum will bind to it, and the unbound antibodies and other proteins will be removed by washing. Then use anti-human IgM fluorescently labeled secondary antibody (cy5-labeled, red) and anti-human IgG fluore...

Embodiment 2

[0046] Embodiment 2 The composition of detection kit of the present invention and its application method

[0047] 1. Kit composition

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of in-vitro diagnostic reagents, and in particular relates to an application of an NCAM1 autoantibody detection reagent to the preparation of a lung cancer screeningkit. According to the application, the autoantibody level of NCAM1 protein in serum of a lung cancer patient is found to be significantly higher than that of a healthy patient for the first time. Thereagent for detecting the autoantibody of the NCAM1 protein is used for preparing the lung cancer screening kit, so that effective screening of lung cancers can be realized.

Description

technical field [0001] The invention relates to the field of in vitro diagnostic reagents, in particular to the use of NCAM1 autoantibody detection reagents in the preparation of lung cancer screening kits. Background technique [0002] Lung cancer is one of the most common malignant tumors in the world. Its morbidity and mortality are increasing year by year. Currently, the incidence rate ranks first in the world, which seriously threatens human health and life. [0003] Lung cancer is a disease that is good at concealment. It often shows clinical symptoms when the disease develops to an advanced stage. 70-80% of lung cancer patients are already in the middle or late stage when they are diagnosed with lung cancer symptoms. The best cure time, five-year survival rate is low. For patients with early lung cancer, timely treatment can greatly improve the 5-year survival rate and quality of life of the patients. Therefore, early diagnosis and effective screening of lung cancer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
CPCG01N33/57423
Inventor 李为民张立
Owner WEST CHINA HOSPITAL SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com